Couverture de Inpatient Update

Inpatient Update

Inpatient Update

De : Mason Turner MD
Écouter gratuitement

À propos de ce contenu audio

Inpatient Update delivers short, practical reviews of new studies that matter to hospitalists—focused on what actually changes decisions on rounds tomorrow. Efficient, evidence-based, and built for the working clinician.

© 2026 Inpatient Update
Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Episode 2: Phenobarbital for DTs, Conservative Dialysis for AKI, and Postop Transfusion Thresholds
      Feb 12 2026

      Send a text

      In Episode 2 of Inpatient Update, your host, Dr. Mason Turner, breaks down three studies that could change what you do on rounds tomorrow:

      • Phenobarbital for alcohol withdrawal — fewer admissions and shorter ED stays during the IV lorazepam shortage natural experiment.
      • Conservative dialysis in AKI requiring RRT (LIBERATE-D) — less routine dialysis, more kidney recovery?
      • Postoperative transfusion thresholds in high–cardiac-risk patients (TOP Trial) — is 7 still enough?

      Articles & PubMed Links

      1. Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department
        Academic Emergency Medicine (2025)
        PubMed: https://pubmed.ncbi.nlm.nih.gov/41147831/
      2. A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury (LIBERATE-D Trial)
        JAMA ( 2026)
        PubMed: https://pubmed.ncbi.nlm.nih.gov/41201895/
      3. Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial
        JAMA (2025)
        PubMed: https://pubmed.ncbi.nlm.nih.gov/41205227/

      REACH OUT:

      Have insight into inpatient medicine?
      Article suggestion?
      Interested in being a guest?

      Email or DM me.


      Follow and subscribe wherever you listen so you never miss the next update.

      Afficher plus Afficher moins
      28 min
    • Episode 1: ERCP Antibiotics, Apixaban Dose in Cancer, and Early Beta-Blockers in Cirrhosis
      Feb 3 2026

      Send a text

      In this pilot episode of Inpatient Update, your host, Dr. Mason Turner, breaks down three clinically relevant studies that could change how you practice tomorrow on the wards:

      1. Pre-ERCP antibiotic prophylaxis — does it reduce post-procedure infections in biliary obstruction?
      2. Reduced-dose apixaban after 6 months in cancer-associated VTE — noninferior and potentially safer?
      3. Early initiation of beta-blockers in cirrhosis with uncomplicated ascites — early signals of benefit.

      Practical take-homes, clear links to evidence, and what to tell your team on rounds.

      Articles & PubMed Links

      1. Is Antibiotic Prophylaxis Warranted in All Patients With Biliary Obstruction Undergoing Endoscopic Retrograde Cholangiopancreatography?: A Systematic Review and Meta-Analysis
        PubMed: https://pubmed.ncbi.nlm.nih.gov/40961256/
      2. Extended Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT)
        PubMed: https://pubmed.ncbi.nlm.nih.gov/40162636/
      3. Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial)
        PubMed: https://pubmed.ncbi.nlm.nih.gov/40689908/
      Afficher plus Afficher moins
      18 min
    Aucun commentaire pour le moment